Iterum Therapeutics plc (ITRMF) EBITDA Margin (2017 - 2025)

Iterum Therapeutics has reported EBITDA Margin for 4 years, with the latest figure at 1982.31% in Q3 2025.

• On a quarterly basis, EBITDA Margin changed N/A year-over-year to 1982.31% in Q3 2025; TTM through Sep 2025 was 5292.31%, a N/A change from a year earlier, with the FY2019 full-year figure at 275732.43%, down 26692242.0% from the prior year.
• EBITDA Margin was 1982.31% for Q3 2025 at Iterum Therapeutics, up from 55313.51% in the prior quarter.
• The five-year high for EBITDA Margin was 1982.31% in Q3 2025, with the low at 1982.31% in Q3 2025.